Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
February 2010
Features
Interventions to Curb the Overuse of Acid-Suppressive Medications on an Inpatient General Medicine Service
A retrospective review was conducted to assess the effect of various interventions on inappropriate prescribing of acid-suppressive agents in the hospital. Providing educational lectures was helpful, but adding a pharmacist to the health care team resulted in the greatest decline in inappropriate use of these drugs.
Randolph E. Regal, BS, PharmD; Amanda D. Osta, MD; and Vikas I. Parekh, MD
Pharmacological and Clinical Differences Between Low-Molecular-Weight Heparins
Implications for Prescribing Practice and Therapeutic Interchange
Although low-molecular-weight heparins (LMWHs) have similar antithrombotic effects, they differ in their pharmacological and biochemical profiles. The authors discuss therapeutic interchange programs for currently available LMWHs and the risks to patients when agents are not clinically interchangeable.
Geno J. Merli, MD, and James B. Groce, PharmD
Meeting Highlights
American Society of Hematology, 51st Annual Meeting and Exposition
Drugs discussed include dasatinib (Sprycel), nilotinib (Tasigna), and imatinib (Gleevec) for patients with chronic myelogenous leukemia; deferasirox (Exjade) for beta-thalassemia major with iron overload; eculizumab (Soliris) for thrombocytopenia; and romiplostim (Nplate) for myelodysplastic syndromes.
Walter Alexander
Pharmaceutical Approval Update
Topics include an influenza vaccine (Fluzone High-Dose) to prevent virus subtypes A and B in older patients; von Willebrand factor/coagulation factor VIII complex (Wilate) to treat spontaneous and trauma-induced bleeding in patients with von Willebrand’s disease; and tranexamic acid (Lysteda) for heavy menstrual bleeding.
Marvin M. Goldenberg, PhD, RPh, MS
Departments
Editorial
Taking AAIM
David B. Nash, MD, MBA, discusses the impact of health care reform on academic departments of medicine and their affiliated training programs.
David B. Nash, MD, MBA
Medication Errors
Tablet Splitting—Only If You “Half” To
Matthew Grissinger, RPh, FASCP, explains how to ensure safety and minimize risks when oral tablets need to be split.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
FDA Plans to Simplify Formats for Consumer Pharmacy Materials
Stephen Barlas discusses the FDA’s plans to simplify the labeling of consumer medical information.
Stephen Barlas
New Drugs/Drug News/New Medical Devices
From Actemra to Wilate, P&T presents the latest studies and information about FDA approvals, drug indications, product recalls, and industry updates.
Drug Forecast
Febuxostat (Uloric), A New Treatment Option for Gout
Dr. Avena-Woods and Dr. Hilas review febuxostat (Uloric) for the treatment of gout.
Carmela Avena-Woods, PharmD, and Olga Hilas, PharmD, MPH, BCPS, CGP
